SEC-sourced researchBeta
OVID
Ovid Therapeutics Inc.
Company comparison ↗
Data passport
- CIK
- 0001636651
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Mar 18, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 566,000.0000 | Mar 18, 2026 |
| December 2025 | 7,252,000.0000 | Mar 18, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 7,252,000.0000 | -17,414,000.0000 | -38,334,000.0000 | 150,934,000.0000 | 20,274,000.0000 | Mar 18, 2026 |
| December 2024 | 566,000.0000 | -26,433,000.0000 | -55,956,000.0000 | 92,167,000.0000 | 23,941,000.0000 | Mar 18, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $7.25M | December 2025 | Mar 18, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $566K | December 2024 | Mar 18, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$17.41M | December 2025 | Mar 18, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$38.33M | December 2025 | Mar 18, 2026 | 10-K |
| Total assetsAssets | $150.93M | December 2025 | Mar 18, 2026 | 10-K |
| Total liabilitiesLiabilities | $20.27M | December 2025 | Mar 18, 2026 | 10-K |